The investigation centers on a Complete Response Letter issued by the U.S. Food and Drug Administration earlier this year. Regulators declined to approve Disc Medicine’s new drug application for bitopertin, citing unresolved uncertainties that require further clinical evidence. This rejection wiped out significant market value in a single session, prompting the legal inquiry into whether the company’s prior public statements accurately reflected the status of its flagship program.

Investors who held shares during the period leading up to the FDA’s decision are being invited to participate in the prospective litigation. Rosen Law Firm, which operates on a contingency fee basis, is currently gathering evidence to determine if the firm can seek recovery for shareholder losses. Phillip Kim, an attorney at the firm, is handling inquiries for those interested in joining the potential class action.